

Beta-lactam Allergy Guideline

Background:

The prevalence of penicillin allergies in the United States (US) has been estimated to be between 8 and 15%. Cephalosporin allergies are less frequent and are reported in approximately 1% of the US population. However, >97% of patients reporting a penicillin allergy are not truly allergic when assessed by skin testing and direct amoxicillin challenge. Among patients with a low severity penicillin allergy, over 95% can tolerate penicillin. This is due to the fact that most penicillin allergies are documented after the occurrence of delayed benign rashes that do not necessarily recur on re-exposure, intolerances due to penicillin, or other symptoms unrelated to an allergy such as urticaria due to a viral infection. Moreover, over 80% of patients with true IgE-mediated penicillin allergy outgrow their allergy after 10 years due to waning sensitization.

Overuse of second line agents such as fluoroquinolones due to over-cautious avoidance of a wide range beta-lactams can have significant negative consequences, including adverse drug reactions, *Clostridioides difficile* super-infection, and antimicrobial resistance.

The purpose of this guideline is to guide clinicians in prescribing antibiotics for inpatients with reported allergic reactions to penicillin or cephalosporin antibiotics by allowing these patients to receive more narrow-spectrum, more effective, less toxic, and/or less costly antibiotic.

Appendices:

Appendix 1: Patient allergy assessment tool (consider utilizing this tool when discussing allergy with your patient)

Appendix 2: Determining type of reaction and action plan

Appendix 3: Cross-reactivity matrix for antibiotics on formulary at CHI Memorial

Appendix 4: Test Dose Procedure

Appendix 1:

Patient allergy assessment tool

- 1) What is the name of the antibiotic you are allergic to?
- 2) Please describe the details of the reaction.
- 3) Was it immediate or a few days after taking it?
- 4) When did your allergy occur?
 - a. < 1 year ago, 1-10 years ago, >10 years ago
- 5) How was the reaction managed and what happened?
- 6) Have you taken any other antibiotics since (amoxicillin, augmentin, keflex, ceftin etc.)?

Appendix 2:

Type of reaction and Action Plan

Dermatological		Respiratory or Systemic		Unknown Reaction	
Clinical manifestation	Severity or Allergy type	Clinical manifestation	Severity or Allergy type	Clinical manifestation	Severity or Allergy type
Childhood rash	Unlikely to be significant	Laryngeal Involvement (“throat tightness”, “hoarse voice”)	Severe	Unknown reaction ≤ 10 years ago	Unknown
Diffuse rash or localized rash/swelling with no other symptoms	>10 years ago or unknown	Respiratory compromise (“shortness of breath”)	Severe	Unknown reaction >10 years or family history	Unlikely to be significant
	≤ 10 years ago				
Angioedema (“lip, facial, or tongue swelling”)	Severe	Anaphylaxis, unexplained collapse	Severe	Renal	
Generalized swelling (outside of angioedema)	Severe	Hematological		Severe renal injury, failure, or AIN	Potential immune mediated
Urticaria (“wheals and hives”)	Non-severe	Low platelets, neutrophils, hemoglobin, eosinophilia	Potential immune mediated	Mild renal impairment	Unlikely immune mediated
Mucosal ulceration (“mouth, eye, or genital ulcers”)	Severe			Severe liver injury, failure	Potential immune mediated
Pustular, blistering or desquamating rash (“skin shedding”)	Severe			Mild hepatic enzyme elevation	Unlikely immune mediated
Reaction Risk (Color Coded) & Action Plan				Gastrointestinal or Neurological	
Appropriate for oral re-challenge or direct de-labeling			Low Risk	GI symptoms (nausea, vomiting, diarrhea)	Unlikely immune mediated
Appropriate for oral re-challenge or using full dose beta-lactam with dissimilar side chain (Appendix 3)			Low Risk	Mild neurological symptoms (headache, depression, mood disorder)	Unlikely immune mediated
May be appropriate for test dose of beta-lactams with dissimilar side chains* or penicillin skin test			Moderate risk		
Not appropriate for allergy testing			High risk	Severe neurological manifestation (seizures, psychosis)	Unknown or unclear mechanism

*If moderate risk penicillin reaction, can consider test dose of cefazolin, 3rd, 4th, 5th generation cephalosporins or carbapenem.

If moderate risk cephalosporin reaction, can consider test dose of cephalosporins with dissimilar side chains (Appendix 3), penicillin (if reaction to 3rd, 4th, or 5th generation cephalosporin), or carbapenem.

Aztreonam full dose can be administered unless reaction was to ceftazidime

Appendix 3:

Cross-reactivity matrix

	Penicillin	Amoxicillin	Ampicillin	Piperacillin	Cefazolin	Cefadroxil	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftazidime	Cefepime	Ceftaroline	Ceftolozane
Penicillin	=						*						
Amoxicillin		=	*	*		*							
Ampicillin		*	=	*		*							
Piperacillin		*	*	=		*							
Cefazolin					=								
Cefadroxil		*	*	*		=							
Cefoxitin	*						=	*					
Cefuroxime							*	=	*	*	*		*
Ceftriaxone								*	=	*	*		*
Ceftazidime								*	*	=	*		*
Cefepime								*	*	*	=		*
Ceftaroline												=	
Ceftolozane								*	*	*	*		=

A box with (*) Indicates that the two antibiotics share a similar or identical side chain and that there is a risk of cross-reactivity between them. Empty boxes indicate a lack of side-chain similarity and a lower risk for cross-reactivity. Cefazolin and Ceftaroline have dissimilar side chains to all other penicillins and cephalosporins.

Appendix 4:

Test Dose Procedure

Note: This procedure is NOT meant to be used for patients with Type II-IV reactions including SJS/TEN, DRESS/DISH, serum sickness, drug-induced cytopenias, other significant laboratory abnormalities such as nephrotoxicity or delayed reactions

- 1) Utilize Appendix 2 to identify appropriate candidates for the test dose
- 2) Review patient's current medications to ensure no antihistamines, famotidine, high dose steroids were given in the last 24 hours as these may mask an allergic reaction
- 3) Obtain patient's verbal consent prior to procedure
- 4) Drug order & monitoring
 - a. Oral rechallenge for de-labeling
 - i. Single dose penicillin VK 250mg (if reported allergy penicillin) or amoxicillin 250mg (if reported allergy amoxicillin or ampicillin)
 - ii. Perform observation every 30 mins for 1 hour post oral challenge
 - b. Test dose of beta-lactam that you intend to use
 - i. Give patient 1/10th of full standard treatment dose (ex: for ceftriaxone (standard dose: 1-2g), formulate 1g dose in 50mL of normal saline and give 1st 5 mins of dose ~160mg)
 - ii. Monitor for 30 minutes. If the patient remains asymptomatic, give the full dose.
 - iii. Monitor patient for 60 more minutes to ensure no reaction
 - iv. Subsequent doses can be given as per hospital's standard protocol
- 5) Profile Anaphylaxis & Acute Drug Hypersensitivity Protocol MCT to be available during the test dose procedure
- 6) If no evidence of reaction, ASP Team to document results of the procedure in the progress notes, remove allergy from medical record and inform patient of the allergy removal

References:

- 1) Castells M, Khan DA, Phillips EJ. Penicillin allergy. *N Engl J Med* 2019; 381:2338-51.
- 2) Krishna MT, Misbah SA. Is direct oral amoxicillin challenge a viable approach for 'low risk' patients labelled with penicillin allergy. *J Antimicrob Chemother* 2019;74(9):2475-79.
- 3) Anstey K, Tsao, L, Otani IM. Drug allergy delabeling programs: recent strategies and targeted populations. *Clin Rev Allergy Immunol.* 2022;62(3):484-504.
- 4) Confino-Cohen Ronit, Rosman Y, Meir-Shafir K, et al. Oral challenge without skin testing safely excludes clinically significant delayed-onset penicillin hypersensitivity. *J Allergy Clin Immunol Pract.* 2017;5(3):669-675.
- 5) Chua KY, Vogrin S, Bury S, et al. The penicillin allergy delabeling program: a multicenter whole-of-hospital health services intervention and comparative effectiveness study. *Clin Infect Dis* 2021;73(3):487-96.
- 6) Devchand M, Kirkpatrick CMJ, Stevenson W., et al. Evaluation of a pharmacist-led penicillin allergy delabelling ward round: a novel antimicrobial stewardship intervention. *J Antimicrob Chemother* 2019; 74(6):1725-30.
- 7) Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: A cohort study. *J Allergy Clin Immunol* 2014;133(3):790–6.
- 8) Blumenthal K. G., et al. Impact of a clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy. *Ann. Allergy. Asthma Immunol.* 115, 294–300.e2 (2015).
- 9) Lin RY. A perspective on penicillin allergy. *Arch Intern Med* 1992;152:930-937.
- 10) Weiss MR. Drug allergy. *Med Clin North Am* 1992;76:857-882.
- 11) DePestel DD, Benninger MS, Danziger L, et al. Cephalosporin use in treatment of patients with penicillin allergies. *Journal of the American Pharmacists Association* 2008;48:530- 540.
- 12) Pichichero ME. Use of selected cephalosporins in penicillin-allergic patients: a paradigm shift. *Diagnostic Microbiology and Infectious Disease* 2006;57:13S-18S.
- 13) Romano A, Viola M, Guéant-Rodriguez RM, et al. Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. *Ann Intern Med* 2007;146(4):266.
- 14) Pichichero ME, Zagursky R. Penicillin and cephalosporin allergy. *Ann Allergy Asthma Immunol* 2014;112:404-12.
- 15) Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of alternative cephalosporins. *J Allergy Clin Immunol* 2015;136:685-691.e683.
- 16) Skalweit MJ. Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections. *Drug Des Devel Ther* 2015;9:2919-25.
- 17) Blumenthal KG, Shenoy ES, Wolfson AR, et al. Addressing inpatient beta-lactam allergies: a multihospital implementation. *J Allergy Clin Immunol Pract* 2017;5:616-25.